Izpisua Belmonte, PhD, Altos Labs, advocates a disease-agnostic approach, but first, he said, “we must understand the mechanism, something that is core to the cell.” ...

System MarketThe global Mesenchymal Stem Cells Market is valued at USD 3.82 Billion in 2024 and is projected to reach a value of USD 9.08 Billion by 2035 at a CAGR (Compound Annual Growth Rate) ...

Stem cell manufacturing landscape is rapidly advancing, driven by major clinical trial successes and new therapy approvals. A ...

The Lupus Foundation of America (LFA) is excited to share that enrollment for the MiSLE (Mesenchymal Stromal Cells in Systemic Lupus Erythematosus) study was officially completed on February 21, 2025 ...

The US Food and Drug Administration (FDA) has approved remestemcel-L (Ryoncil, Mesoblast Ltd), an allogeneic bone marrow‒derived mesenchymal stromal cell (MSC) therapy for steroid-refractory acute ...

Mesoblast’s Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved ...

Ryoncil ® (remestemcel-L) is the only allogeneic mesenchymal stromal cell therapy approved by U.S. Food and Drug Administration (FDA) for any indication. As documented in the Company’s Biologic ...

The MSC market offers significant opportunities in regenerative medicine, cosmeceuticals, and cultured meat production. Leveraging their regenerative and immuno-evasive properties, MSCs are key in ...

The product is sonruvetcel suspension for injection – a potential first-in-class, uterine-derived allogeneic mesenchymal stromal cell therapy for cats with refractory feline ...